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ABSTRACT
Background Reaching the therapeutic target of
remission or low-disease activity has improved outcomes
in patients with rheumatoid arthritis (RA) signiﬁcantly.
The treat-to-target recommendations, formulated in
2010, have provided a basis for implementation of a
strategic approach towards this therapeutic goal in
routine clinical practice, but these recommendations
need to be re-evaluated for appropriateness and
practicability in the light of new insights.
Objective To update the 2010 treat-to-target
recommendations based on systematic literature reviews
(SLR) and expert opinion.
Methods A task force of rheumatologists, patients and
a nurse specialist assessed the SLR results and evaluated
the individual items of the 2010 recommendations
accordingly, reformulating many of the items. These were
subsequently discussed, amended and voted upon by
>40 experts, including 5 patients, from various regions
of the world. Levels of evidence, strengths of
recommendations and levels of agreement were derived.
Results The update resulted in 4 overarching principles
and 10 recommendations. The previous
recommendations were partly adapted and their order
changed as deemed appropriate in terms of importance
in the view of the experts. The SLR had now provided
also data for the effectiveness of targeting low-disease
activity or remission in established rather than only early
disease. The role of comorbidities, including their
potential to preclude treatment intensiﬁcation, was
highlighted more strongly than before. The treatment
aim was again deﬁned as remission with low-disease
activity being an alternative goal especially in patients
with long-standing disease. Regular follow-up (every
1–3 months during active disease) with according
therapeutic adaptations to reach the desired state was
recommended. Follow-up examinations ought to employ
composite measures of disease activity that include joint
counts. Additional items provide further details for
particular aspects of the disease, especially comorbidity
and shared decision-making with the patient. Levels of
evidence had increased for many items compared with
the 2010 recommendations, and levels of agreement
were very high for most of the individual
recommendations (≥9/10).
Conclusions The 4 overarching principles and 10
recommendations are based on stronger evidence than
before and are supposed to inform patients,
rheumatologists and other stakeholders about strategies
to reach optimal outcomes of RA.
The treatment of rheumatoid arthritis (RA) has
undergone dramatic changes over the past 20 years,
which may be subsumed under ﬁve captions: (i)
availability of reliable assessment tools for clinical
trials and practice;1–5 (ii) appreciation of the import-
ance of early diagnosis and concomitant start of
conventional synthetic disease-modifying antirheu-
matic drug (csDMARD) therapy, including their
combination with low-dose glucocorticoids;6–10 (iii)
recognition of the potential to halt or at least min-
imise damage progression upon attainment of good
clinical states;11 12 (iv) appreciation that methotrex-
ate, if applied in accordance with relevant insights
on dose and folate use, is a powerful agent and the
anchor drug in RA;13–15 and (v) development and
approval of new biologic DMARDs (bDMARDs). In
recent years, this knowledge has been further conso-
lidated, not least by virtue of deﬁning a treatment
target and applying tight control and respective
therapeutic adaptations to reach this target.16–18
This paradigm has been incorporated into the
‘treat-to-target’ recommendations.19 Indeed, this
principle is also advocated by recommendations for
the management of RA.20–24
In line with all these developments, the main
pillars of the 2010 treat-to-target recommendations
were the deﬁnition of a treatment target, namely
remission or at least low-disease activity (LDA); the
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assessment of disease activity using composite measures that
include joint counts; the regular adaptation of therapy if the
target is not achieved within a particular timeframe; the
accounting for individual patient aspects including risks when
pursuing the therapeutic goals; and the shared decision-making
with the patient. The treat-to-target (T2T) recommendations
are generic as they do not advocate any particular type of inter-
vention, but just the principle that should be adhered to, irre-
spective of the availability of particular drugs. They were based
on the rationale of ﬁrst deﬁning the aim and then considering
how one may generally approach reaching that goal, before
deﬁning means to arrive there. Attaining (or not attaining) this
target can serve as a benchmark for an individual practice,
centre or country. The target was deﬁned as clinical remission
or at least low-disease activity since these states convey the best
and second best outcomes in RA.25–27 At the time of the formu-
lation of the recommendations, a task force of the American
College of Rheumatology (ACR) and the European League
Against Rheumatism (EULAR) was still engaged in elaborating
new remission criteria that has meanwhile been accomplished;28
therefore, in the treat-to-target and related recommendations,
remission originally had been deﬁned in general terms, but ref-
erence was made to this activity as an ultimate deﬁnition of clin-
ical remission.19 21
There are several reasons to reconsider the treat-to-target
recommendations. When they were developed, several of the
items were based on expert opinion or indirect support rather
than stringent, direct evidence and, therefore, it was deemed advis-
able to look out for new pieces of evidence for or against one or
more of the items, as also stated as research agenda at that time.
Beyond this aspect, some criticism had arisen.29 30 While most
points of this critique had actually been already quite clearly
accounted for in the recommendations or the accompanying text,
it indicated that the verbalisation and/or the positioning of some
of the recommendations might have not been sufﬁciently clear.
Also, the adherence to the treat-to-target recommendations in clin-
ical practice may be low,31 despite all the evidence regarding the
importance of this approach. Therefore, revisiting the formulation
of individual recommendations in line with available evidence
and/or reassessment of expert opinion seemed desirable. Finally,
all recommendations should be revisited every few years for their
timeliness, appropriateness and accuracy, especially in the light of
new developments in the ﬁeld. Such reshaping of the recommen-
dations may also help improving adherence of health professionals
to the recommendations32 and adherence of patients to therapies
they have agreed upon with their physicians.
For all these reasons, a Task Force was convened to
re-evaluate the treat-to-target recommendations with the object-
ive of addressing all overarching principles and recommenda-
tions individually for their content and contextual positioning
as well as evaluating the newest evidence accrued since the
development of the 2010 treat-to-target recommendations
based on a systematic literature review (SLR).33
METHODS
This endeavour consisted of several stages. Initially, a Steering
Committee comprised of rheumatologists from several areas of
the world and a patient was brought together in 2012 to discuss
the potential need for updating the recommendations. During
these deliberations, questions related to the practicability of some
of the items; aspects of risks on the way to attain the treatment
target; the issue of comorbidities both from the viewpoint of
their association with active RA and as potential contraindica-
tions for intensifying therapy; the role of work productivity; and
reduction or withdrawal of therapy upon achievement of the
target were distilled in an iterative discussion process as import-
ant themes that had not, or not sufﬁciently, been addressed in
2010. Also, in the SLR performed for the 2010 recommenda-
tions,34 only very few publications had focused on differences
between treatment strategies as primary endpoint, namely com-
paring a treatment strategy towards a particular target with other
therapeutic approaches, and these almost exclusively dealt with
early but not established RA. As a consequence of these discus-
sions, details for an SLR of studies published between 2008 and
2012 were elaborated and an initial search performed by
MSch. When the Steering Committee reconvened at the end of
2012 and discussed these SLR results, it was disappointing to see
that evidence for many of the questions addressed was still
scarce. Therefore, it was decided to wait for additional informa-
tion and the re-evaluation of the recommendations was post-
poned. A new SLR that accounted for the literature accumulated
between 2012 and April 2014 was performed in the middle of
2014 by MSt and TS. These results were presented to the
Steering Committee.33 Indeed, novel evidence related to
the questions posed was found, expanding the data obtained by
the initial SLR34 and the SLR performed in 2012.33 At a new
meeting, the Steering Committee was informed on the results of
the SLRs and subsequently revisited the individual recommenda-
tions and performed a preliminary reformulation, where neces-
sary. The committee also evaluated the sequence of the
recommendations for logical coherence or risk of being over-
looked. Aspects to be discussed in the text accompanying the
individual points were documented.
In a next step, the proposal of the Steering Committee was
presented to a large Task Force of 33 expert individuals,
which comprised rheumatologists from many regions of the
world (Australia, Europe, Japan, Latin America and North
America), 5 patient representatives who had either been
already involved in the development of the original recom-
mendations or were identiﬁed as having particular interest in
this area of research, and a rheumatology nurse. After presen-
tation of the steering group’s proposal and the background
for it, three breakout groups were formed to address (a) the
overarching principles, (b) recommendations 1–5 and (c)
recommendations 6–10. Chaired by a patient representative
(group dealing with the overarching principles) and rheuma-
tologists (the other two groups), further discussions took
place during these breakout sessions and the proposed word-
ings reformulated as deemed appropriate, with majority votes
where controversy existed. It was agreed that individual items
of the 2010 recommendations should only be changed based
on new evidence, expansion of knowledge or if the wording
appeared not being sufﬁciently clear. The results obtained by
the breakout groups were reported to the whole Task Force,
which then discussed these proposals, amended them and
arrived at ﬁnal wordings that were subjected to an anonymous
voting process using voting cards. Items that achieved at least
a two-third majority (≥67%) were taken as ﬁnal recommenda-
tion in the exact way as they had been worded. Items that did
not attain such majority approval straight away were
re-discussed, re-formulated and re-voted on, until the majority
was achieved.
In a ﬁnal exercise, the bullet points were sent to each partici-
pant and additional members who could not be present at the
face-to-face meeting by email to determine the level of agree-
ment using an 11-point numerical rating scale (0=I do not
agree at all, 10=I completely agree). At this stage, no changes to
the wording could be made unless a mistake had been detected.
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Also, the ﬁnal text of the manuscript was sent to all participants
for their comments and ultimate approval.
RESULTS
The new evidence base
The two SLRs revealed a total of 176 T2T-related publications,
of which 6 were found to provide new evidence that was useful
for the update of the recommendations.33 A few randomised
controlled approaches or cohort studies offered direct support,
while others supplied indirect evidence found useful to expand
the recommendations. Two studies of patients with early RA tar-
geted ‘remission’ by the disease activity score (DAS) or DAS28
compared with usual care;35 36 another study in early RA focused
at low-disease activity;37 a further investigation compared two
cohorts of patients with early RA, one with a targeted and the
other one with a conventional approach;38 and one comparative
cohort study addressed treatment to target of DAS28 <2.6
versus conventional therapy in late RA;39 all these studies con-
ﬁrmed that a targeted therapy is superior to conventional thera-
peutic approaches, now even including a study on late RA.40 Two
studies compared treatment approaches targeting good clinical
outcomes versus sonographic remission, showing similar out-
comes.41 42 One study compared the presence of comorbidities
in relation to different deﬁnitions of remission and found that
with ACR–EULAR remission criteria comorbidities such as osteo-
porosis were signiﬁcantly less frequent than with less stringent
criteria, and there was even a similar trend for cardiovascular
disease,43 in line with data showing that cardiovascular risk is sig-
niﬁcantly lower with stringent remission than active disease and
similar to that of the healthy population.44 Two studies compared
different deﬁnitions of remission for residual sonographic activity
and showed signiﬁcantly lower power Doppler scores with ACR–
EULAR than less stringent deﬁnitions.45 46
With this database at hand, the steering committee discussed
the limitations of the treat-to-target recommendations and
potential means to adapt them. Many themes were addressed:
clinical versus ‘imaging’ or ‘laboratory’ remission (the latter
meaning remission by non-clinical means); minimisation of
comorbidities, especially cardiovascular, but also the risk that
LDA or remission may not be targeted by rheumatologists
because comorbidities preclude intensifying therapy; individua-
lised therapy; work productivity and work-force maintenance
aspects; and factors confounding the treatment target.
After the discussions on the SLR, its consequences for the
recommendations and the rewording and repositioning propo-
sals in relation to the 2010 recommendations as suggested by
the steering committee and in the breakout groups all items
underwent voting and the resulting recommendations are shown
in table 1; for comparative purposes, the old version is pre-
sented in small font. Table 2 reveals the results of the ballots,
the levels of evidence and grades of recommendation and the
levels of agreement.
Overarching principles
A. The treatment of RA must be based on a shared decision
between patient and rheumatologist. While this principle
remained unchanged, it was discussed that the follow-up of
patients with RA and therapeutic dialogues are increasingly
also involving other healthcare professionals (HCPs) than
physicians, particularly specialist nurses. In healthcare
systems where this is already established, the shared
decision-making also has to include these HCPs, thus involv-
ing the whole team in the care of RA. All 33 participants
voted in favour of the statement.
B. The primary goal of treating patients with RA is to maxi-
mise long-term health-related quality of life through
control of symptoms, prevention of structural damage,
normalisation of function and participation in social and
work-related activities. Two changes were made to the pre-
vious item B: a minor one, where ‘the patient’ was
replaced by ‘patients’; but more importantly, the previous
item B ended with ‘… social participation’ which was
changed to ‘participation in social and work related activ-
ities’. It was deemed particularly important to include
aspects of work productivity and employment, especially
since work participation has been associated with a better
quality of life,47 which is also implied by using the term
‘through’. Moreover, participation in work is an important
part among the categories of the WHO’s International
Classiﬁcation of Functioning, Disability and Health.48
Other aspects mentioned while discussing this item were
comorbidities, including osteoporosis and cardiovascular
risk, and systemic features of RA, but also the role of
comorbidities as contraindication to amend therapy.
However, it was decided by majority vote to only mention
this in the text accompanying this item as an important
consideration when treating RA but not to include it in
the current wording of the point, especially also because
comorbidity is mentioned speciﬁcally in one of the
current recommendations (recommendation no. 7).
C. Abrogation of inﬂammation is the most important way to
achieve these goals. This item remained unchanged com-
pared with the 2010 version. As during the deliberations
4 years ago, the term ‘abrogation’ was discussed and also the
question raised if the most important aspect was really
inﬂammation, but at the end of these discussions everyone
was convinced that this point should remain as it was since
there were no data available allowing to make any other
conclusion than that interfering with the inﬂammatory
response was of utmost importance for optimal outcomes.
D. Treatment to target by measuring disease activity and adjust-
ing therapy accordingly optimises outcomes in RA. Also, this
item remained unchanged compared with 2010; there was
no further discussion and full agreement within the Task
Force (33 positive votes).
Final set of 10 recommendations on treating RA to target
based on both evidence and expert opinion*
Before addressing the recommendations individually, it was
decided to add a footnote (asterisk) to the heading of the table
to ensure the recognition that the text accompanying each item
is an integral part of the recommendations and that any inter-
pretation that does not account for the information provided in
the text should be seen as wrong.
1. The primary target for treatment of RA should be a state of
clinical remission. This ﬁrst item was not changed at all
versus 2010 and seen as the cardinal point of the recom-
mendations. Clinical remission has consistently been shown
to convey better outcomes than other disease activity states,
even low-disease activity.11 25 26 49 Meanwhile, also two
studies targeting DAS28<2.6 compared with conventional
not DAS28-steered therapy, one in early RA and one in
established RA, showed a signiﬁcant advantage in favour of
targeting this activity state.36 39 While the Task Force dis-
cussed in depth whether the term ‘clinical remission’
should be changed or expanded to include ‘imaging remis-
sion’ or ‘laboratory remission’, there was ﬁnal agreement
on the term clinical remission, especially as deﬁned by the
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ACR–EULAR remission criteria for clinical trials and prac-
tice,28 since the vast majority of the literature, if not the
entire inﬂammatory rheumatology literature addressing
‘hard outcomes’ of RA, like radiographic changes, disability
and quality of life, has been based on clinical observations,
not on observations using imaging techniques. Upon fulﬁl-
ment of clinical remission according to the ACR–EULAR
deﬁnition, functional and structural outcomes are maxi-
mised and only minimal abnormalities can be detected by
imaging such as sonography.45 46 50 Also, a ﬁrst study tar-
geting a clinical low-disease activity state compared with
targeting sonographic remission revealed no major differ-
ences in clinical or functional outcomes despite the use of
low-disease activity rather than ACR–EULAR deﬁned
remission as the clinical target.42 On the other hand, some
data indicate that there may still be residual active synovitis
by sonographic examinations in patients in clinical remis-
sion51 and, therefore, further studies on sonography and
MRI, especially in relation to important long-term
outcomes, need to be awaited. Given all these data,52
imaging remission was not included into the current update
of the recommendations, leaving clinical remission as the
therapeutic target.
2. Clinical remission is deﬁned as the absence of signs and
symptoms of signiﬁcant inﬂammatory disease activity. Also,
this point was not changed. There was a major discussion
ongoing as to which remission criteria should be used.
Whereas with few exceptions everyone agreed that compos-
ite measures, in particular Clinical Disease Activity Index
(CDAI), DAS, DAS28 or Simpliﬁed Disease Activity Index
(SDAI),53 should be generally used to assess disease activity
(see also item 4), several participants felt that, despite the
existence of the new preliminary ACR–EULAR remission
deﬁnition,28 one should not dismiss DAS and DAS28 remis-
sion, while others were of the opinion that the new deﬁn-
ition of remission (Boolean or SDAI-based) should be used,
to which the 2010 Task Force had already referred to, in
particular given even considerations of its sonographic
Table 1 The updated recommendations (2014), including a comparison with the 2010 version
Overarching principles*
2014 2010†
A. The treatment of rheumatoid arthritis must be based on a shared decision
between patient and rheumatologist
A. The treatment of rheumatoid arthritis must be based on a shared decision
between patient and rheumatologist
B. The primary goal of treating patients with rheumatoid arthritis is to maximise
long-term health-related quality of life through control of symptoms,
prevention of structural damage, normalisation of function and participation in
social and work-related activities
B. The primary goal of treating the patient with rheumatoid arthritis is to maximise
long-term health-related quality of life through control of symptoms, prevention
of structural damage, normalisation of function and social participation
C. Abrogation of inflammation is the most important way to achieve these goals C. Abrogation of inflammation is the most important way to achieve these goals
D. Treatment to target by measuring disease activity and adjusting therapy
accordingly optimises outcomes in rheumatoid arthritis
D. Treatment to target by measuring disease activity and adjusting therapy
accordingly optimises outcomes in rheumatoid arthritis
Final set of 10 recommendations on treating rheumatoid arthritis to target based on both evidence and expert opinion*
2014 2010
1. The primary target for treatment of rheumatoid arthritis should be a state of
clinical remission
1. The primary target for treatment of rheumatoid arthritis should be a state of
clinical remission
2. Clinical remission is defined as the absence of signs and symptoms of
significant inflammatory disease activity
2. Clinical remission is defined as the absence of signs and symptoms of
significant inflammatory disease activity
3. While remission should be a clear target, low-disease activity may be an
acceptable alternative therapeutic goal, particularly in long-standing disease
3. While remission should be a clear target, based on available evidence
low-disease activity may be an acceptable alternative therapeutic goal,
particularly in established long-standing disease
4 The use of validated composite measures of disease activity, which include
joint assessments, is needed in routine clinical practice to guide treatment
decisions
6. The use of validated composite measures of disease activity, which include
joint assessments, is needed in routine clinical practice to guide treatment
decisions
5 The choice of the (composite) measure of disease activity and the target value
should be influenced by comorbidities, patient factors and drug-related risks
9. The choice of the (composite) measure of disease activity and the level of the
target value may be influenced by consideration of comorbidities, patient
factors and drug-related risks
6. Measures of disease activity must be obtained and documented regularly, as
frequently as monthly for patients with high/moderate disease activity or less
frequently (such as every six months) for patients in sustained low-disease
activity or remission
5. Measures of disease activity must be obtained and documented regularly, as
frequently as monthly for patients with high/moderate disease activity or less
frequently (such as every 3–6 months) for patients in sustained low-disease
activity or remission
7. Structural changes, functional impairment and comorbidity should be
considered when making clinical decisions, in addition to assessing composite
measures of disease activity
7. Structural changes and functional impairment should be considered when
making clinical decisions, in addition to assessing composite measures of
disease activity
8. Until the desired treatment target is reached, drug therapy should be adjusted
at least every three months*
4. Until the desired treatment target is reached, drug therapy should be adjusted
at least every three months
9. The desired treatment target should be maintained throughout the remaining
course of the disease
8. The desired treatment target should be maintained throughout the remaining
course of the disease
10. The rheumatologist should involve the patient in setting the treatment target
and the strategy to reach this target
10. The patient has to be appropriately informed about the treatment target and
the strategy planned to reach this target under the supervision of the
rheumatologist
The actual changes are highlighted in the online supplementary table.
*As worded, these recommendations constitute solely a brief summary of the discussions on individual aspects of the Task Force’s activity. The Task Force specifies that these
recommendations must not be interpreted without taking the respective text accompanying each item into account.
†The numbers at the left of the 2010 recommendations refer to the original numbering at that time.
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correlates (see above). It was then argued that the ACR–
EULAR remission criteria had been developed for clinical
trials, but this view was contended by the fact that also
remission deﬁnitions for clinical practice (Boolean criteria
without C-reactive protein (CRP) and CDAI remission cri-
teria) had been presented in the ACR–EULAR publica-
tion.28 Moreover, evidence that the residual disease activity
in the presence of DAS28 scores <2.6 is associated with
progression of joint damage and some functional impair-
ment has accumulated since the time of formulating the
2010 recommendations. Indeed, patients in DAS28 remis-
sion not fulﬁlling ACR–EULAR remission criteria compared
with those achieving ACR–EULAR remission (Boolean- or
index-based) may have a large number of residually swollen
joints,54–56 show more damage progression, worse physical
function, worse quality of life and increased rates of
comorbidities. DAS28 remission is thus not easily compat-
ible with the term remission.27 46 57–59 Some fears
were raised that using stringent remission criteria would
allow for achievement by only few patients and might
lead to overtreatment, but this view was opposed by point-
ing to the relatively large frequency of attaining these
criteria in clinical practice and trials of patients with early
RA.60 61 The signiﬁcant residual disease activity that can
be observed with DAS28<2.6 has been debated for
long28 45 46 54 55 62 63 and is associated with progression of
joint damage.57 64 Also, a recent publication evaluating
several clinical trials addressed the underestimation of
disease activity by the DAS28 remission criteria.65
Important in this context is further that the US Food and
Drug Administration classiﬁes DAS28<2.6 as reﬂection of
low-disease activity,66 which is in line with all of the above
notions. It was further mentioned that clinical remission
was mainly a treatment goal for early disease and that there
is an alternative target of low-disease activity, especially for
established disease (see item 3), while in early disease one
would aim for stringent remission with a minimum of
residual disease activity. Moreover, since some of the dis-
cussions focused on imaging (sonographic) remission that is
even more difﬁcult to achieve, stringent clinical remission
as deﬁned by ACR–EULAR may currently be the deﬁnition
best reﬂecting the wording of item 2, leaving other deﬁni-
tions reﬂecting low-disease activity as alternative targets
(see item 3).
Another aspect of debate around this recommendation
was the term ‘signiﬁcant’. Some participants suggested to
delete the term ‘signiﬁcant’ and thus just deﬁne clinical
remission as the ‘absence of signs and symptoms of disease
activity’; however, that would have made even the ACR–
EULAR remission criteria look insufﬁciently stringent, as
they allow for a single residual swollen and tender joint
(Boolean-based and index-based criteria) or possibly two of
either plus none of the other joint count (index-based cri-
teria). Thus, it was decided in the course of the delibera-
tions to ﬁrst vote on the sentence maintaining the term
‘signiﬁcant’ that indeed received a unanimous result (33
‘yes’). Notwithstanding all these discussions, maintaining
the deﬁnition of remission as the ‘absence of signs and
symptoms of signiﬁcant inﬂammatory disease activity’ has
been further supported by the evidence mentioned above
since residual joint swelling beyond one or two, as an
obvious sign of signiﬁcant inﬂammatory activity, is asso-
ciated with damage progression.57
3. While remission should be a clear target, low-disease activ-
ity may be an acceptable alternative therapeutic goal, par-
ticularly in long-standing disease. The meaning of this
recommendation remained unchanged, but it was shortened
by deleting the insert ‘based on available evidence’ because
that evidence had further increased over the last four years,
making obsolete to speciﬁcally point it out. It was further
discussed that comorbidities may be present that might pre-
clude the intensiﬁcation of therapy to target remission,
especially in long-standing disease. However, this aspect
was not included here since it was felt that ‘long-standing’
disease in itself inferred not only RA with signiﬁcant
damage but also the potential presence of comorbidities
and that this would be dealt with in a subsequent recom-
mendation anyway (no. 5). Moreover, the word ‘particu-
larly’ implied that low-disease activity could also be a target
in early disease, although—as the item is worded—low-
disease activity is not a preferred state for early disease but
may be so more in established RA. Importantly, deﬁning
the alternative to remission as being low-disease activity in
the context of treatment targets precludes any other state,
such as moderate disease activity, as a therapeutic goal,
although even this viewpoint is to some extent counterba-
lanced for exceptional situations by recommendation 7. It
was also regarded important to recommend documentation
of the chosen treatment target in the ﬁles and to share this
decision with the patient, in line with overarching principle
A (shared decision). Importantly and to reiterate, the Task
Force does not insinuate to replace the target of remission
by the alternative target of low-disease activity but rather
implies that if remission cannot be achieved for any reason
(such as in patients with long-standing disease), low-disease
activity is an alternative and valid target, but any other state
than low-disease activity would usually not be acceptable.
However, patient factors, such as comorbidities, have to be
taken into account in the course of a shared decision with
the patient when deﬁning the treatment target and the way
to arrive there.
4. The use of validated composite measures of disease activity,
which include joint assessments, is needed in routine
Table 2 Evidence, grade of recommendation, agreement and votes for each of
the recommendations (as pertinent)
Item
Category of
evidence
Grade of
recommendation
Level of
agreement
Percentage of votes
at last ballot*
1 1b A 9.53±0.80 100
2 2c B 9.50±0.69 100
3 1b, 4† A, D 9.68±0.57 97
4 1b, 4V‡ A, D 9.26±1.13 97
5 4 D 9.18±1.09 67
6 1b, 4§ A, D 9.21±1.09 94
7 4 D 9.47±1.06 67
8 1b, 4¶ A, D 9.08±1.08 67
9 2c B 9.61±0.75 67
10 4 D 9.73±0.77 67
*Most items required just one ballot and none underwent more than two votings.
†1b for the evidence that low-disease activity is a good treatment target, but 4
because it is expert opinion that it is an alternative goal for remission.
‡1b for the evidence that the use of composite measures is important compared with
routine care, but no large study has compared measures that included joint counts
with some that did not; therefore 4 for the joint count part.
§1b for the necessity to use composite measures, 4 for some of the time components
mentioned.
¶1b for regular adjustment that was mostly done every three months, but 4 for the
timelines mentioned, since no comparisons between adjustments at different time
points were done.
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clinical practice to guide treatment decisions. The wording
of this recommendation has not been changed, but it was
shifted upward from its previous position as no. 6. This
change in order had two reasons: ﬁrst, it appeared to be
more rational to refer to the means to measure disease
activity immediately after having deﬁned the therapeutic
targets, namely clinical remission or low-disease activity;
second, making this item more visible in the order of
recommendations reﬂects the Task Force’s conviction on
the importance of regular disease activity assessment by
appropriate methods. As before, the vast majority of the
Task Force members felt that the measures used should
comprise joint counts, and mentioning ’joint assessments’
(plural) refers to the evaluation of both swollen and tender
joint counts. It has been known for long that swollen joint
counts correlate with progression of joint damage,67–70
while tender joint counts relate to physical function.68 The
respective instruments have been discussed in a EULAR–
ACR publication,71 and the choice of the instrument
should be recorded in the ﬁles. There was a discussion
whether one should also recommend using an instrument
purely based on patient-reported outcomes, such as the
RAPID3,72 plus a swollen joint count, but this would
require the rheumatologist to consider two scores rather
than just one and thus would not be in line with the term
‘composite measures…which include joint assessments’. On
the other hand, a recent study that compared a score com-
prising joint counts with one that did not, revealed higher
frequencies of low-disease activity with the former, indicat-
ing that by using the measure not containing joint counts,
patients are at risk of being overtreated when aiming for
low-disease activity,73 because a larger number of patients
would appear to have moderate or high disease activity
than is truly the case according to the composite measure
that includes joint counts. At this point, it is noteworthy
that it is mostly expert view to use composite measures that
include joint counts, since no head-to-head study compar-
ing such measures has been performed. However, this
expert view is based on the consistently shown relationship
between swollen joint counts and damage progression.74
5. The choice of the (composite) measure of disease activity
and the target value should be inﬂuenced by comorbidities,
patient factors and drug-related risks. This recommenda-
tion, previously comprised in no. 9, underwent a change in
wording in two respects: ﬁrst, the prior word ‘may’ was
replaced by ‘should’, making a stronger point on the choice
of other treatment targets than remission (or even low-
disease activity) under certain circumstances (see below);
second, old no. 9 stated “…inﬂuenced by consideration of
co-morbidities,…” while the ‘consideration’ has now been
removed and the recommendation calls for adaptation of
treatment targets according to the presence of comorbid-
ities, patient factors and drug-related risks. Moreover, this
recommendation was shifted from its previous position as
no. 9 of 10 to no. 5. Again, logic and the desire to give
more prominence and thus attention to this recommenda-
tion were driving this decision. Logic, since this item now
follows immediately after the recommendation on the
importance to apply composite measures of disease activity
and brings some respective caveats forward. Since in par-
ticular the presence of some comorbidities, such as severe
cardiovascular disease, uncontrolled diabetes, or impaired
renal or hepatic function, may preclude attempts to change
treatment geared at reaching the main treatment target, the
therapeutic goal may have to be different in such patients.
Similar thoughts pertain to contraindications or safety
aspects; if a patient suffers from recurrent infections, one
will likely refrain from intensiﬁcation of therapy to avoid
risky overtreatment. Regarding the choice of the composite
measure and the potential need to employ other instru-
ments, such as comorbidities that increase or decrease acute
phase reactants (which will confound scores that comprise
erythrocyte sedimentation rate or CRP), some of our trad-
itional composite measures may not be useful tools and
other means may have to be the focus of disease activity
assessment in such patients. On the other hand, with some
particular aspects accompanying RA, such as pain hypersen-
sitivity, patient-reported outcomes may not reﬂect the
inﬂammatory events correctly but will likely be oversha-
dowed by the comorbidity; this relates to the patient global
assessment, but also to function and quality-of-life ques-
tionnaires as well as tender joint counts. Importantly, and
in line with what was stated above, the instrument used to
assess disease activity and the treatment target should be
documented. The discussion partly focused around combin-
ing this point with the previous one, but it was felt that
they address different issues and that this cautionary recom-
mendation might be ‘diluted’ if it became an appendix of
the previous one. Moreover, some criticism had arisen
around this particular aspect29 despite its prior existence
and, therefore, its presentation as a distinct recommenda-
tion was deemed important. It is now less likely to be over-
looked. In the course of the discussion, another important
point emerged: while comorbidities may preclude intensiﬁ-
cation of therapy due to perceived risks, some comorbid
conditions (such as amyloidosis or cardiovascular disease)
are a consequence of active inﬂammation and, therefore,
they may even require to aim for a target of remission
without tolerance of low-disease activity; indeed, there has
been a signiﬁcant survival advantage in recent years with
modern treatment approaches.75–79 Also, in elderly patients
with RA intensive therapy is frequently avoided out of the
perception that they may not require it,80 although there is
evidence against such contention.81 82 Another ‘patient
factor’ to be considered is work capacity and its impair-
ment. Moreover, it needs to be borne in mind that
comorbidities and other patient factors may change in the
course of the disease and its treatment, which may impact
the maintenance of the treatment target as requested in rec-
ommendation 9. Thus, overall, this recommendation relates
to a personalised approach of the treatment strategy, con-
sidering all factors related to the individual patient.
6. Measures of disease activity must be obtained and documen-
ted regularly, as frequently as monthly for patients with
high/moderate disease activity or less frequently (such as
every six months) for patients in sustained low-disease activ-
ity or remission. There was only a small change regarding
this item, which was previously no. 5. It had stated ‘such as
every 3–6 months’ for control examinations in patients
who sustain the therapeutic target of low-disease activity or
remission, maintenance of remission being an important
goal. However, 3-month intervals were felt undue for this
population of patients, and some rheumatologists may even
consider less frequent control examinations than every six
months to be appropriate. Nevertheless, assessments at
different time points have not been compared and therefore
most of these time-related aspects have a low level of evi-
dence, but strong expert opinion with good agreement, as
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indicated by the 94% positive vote. This recommendation
also explicitly calls for documentation of the measure of
disease activity chosen in the patient’s chart. On the other
hand, since with very active disease frequent adaptation of
therapy may be needed, the Task Force reiterated the
potential need for monthly controls in such situations.
Moreover, as will be also stated in a subsequent recommen-
dation (no. 9), the necessity for maintenance of remission
(or low-disease activity) is already mentioned at this point
in time. However, even patients in sustained remission must
be assessed at certain intervals to ensure maintenance of
the good outcome and lack of adverse events. In the course
of sharing decisions with the patient, it is also important to
advise the patient to reach out for the rheumatologist
earlier than at the predetermined time point if the condi-
tion changes unexpectedly. In many countries, follow-up
assessments are undertaken by health professionals other
than physicians in the setting of a multidisciplinary care.
Irrespective of the assessing person, numerous practice
trials have revealed the importance of regular disease activ-
ity assessments. Without such regular evaluations using
respective instruments, patients will be undertreated and
therefore may encounter worse structural and functional
outcomes, but also more comorbidities. It was also dis-
cussed if longer intervals should not be suggested for
patients who have reached remission. However, the major-
ity of participants felt that a ﬁrst achievement of remission
may still be a vulnerable situation and longer intervals
should only be considered for patients in sustained remis-
sion; also the duration to which the term ‘sustained’ would
pertain was not clear—3 months or 6 months might be
considered as the absolute minimum requirement in this
respect.
7. Structural changes and functional impairment and
comorbidity should be considered when making clinical deci-
sions, in addition to assessing composite measures of disease
activity. ‘…and comorbidity’ was now added to this recom-
mendation to reiterate the importance of considering
comorbidities in the context of making clinical decisions.
Otherwise, this item points again to the importance of using
composite activity measures. However, it also addresses the
issue of structural changes since the presence of early joint
damage is a risk factor for further damage.22 67 69 In this
context, estimation (not scoring) of damage progression may
be done upon regular (such as annual) performance of
radiographs. On the other hand, no speciﬁc imaging method
is mentioned in this bullet point and some rheumatologist
may wish to assess progression of damage using MRI or son-
ography, although joint space narrowing that has a particular
impact on physical function83 may be more easily discernible
on radiographs. Further, impairment of physical function
and work performance may sometimes be associated with a
residual activity of a functionally important joint (eg, wrist
or ankle) despite improvement in (most) other joints; thus,
while the overall status may appear good, this impairment
may have to direct particular treatment decisions.
Importantly, it has also to be borne in mind that functional
impairment in patients with RA may not only be due to the
joint disease but also a consequence of comorbidities;
indeed, even patients in stringent remission may experience
high disability scores as a consequence of such concomitant
diseases.84–86
8. Until the desired treatment target is reached, drug therapy
should be adjusted at least every three months. The
wording of this recommendation (originally no. 4) was not
changed. Of particular importance, almost all practice trials
have shown that patients under routine care that is not
informed by a composite measure of disease activity have
much worse outcomes than patients in whom treatment
decisions are based on the disease activity assessment by
such instruments.16 This is an important concept since the
observations that routine care that does not apply clinical
scoring and a targeted therapeutic approach suggest that
patients with RA have been signiﬁcantly undertreated. The
shift to its new positioning, therefore, does not imply that
the Task Force did not appreciate this point as sufﬁciently
important to be among the initial items; on the contrary,
the Task Force felt, just as before, that this is a key recom-
mendation. However, appropriate adjustments of therapy
have already been implied in items 4 and 6, where we
advocate guidance of treatment decisions by the use of
composite measures and a high frequency of taking these
measures in the presence of active disease. ‘Adjust’ is then
an expansion of the term ‘guide’, but it does not primarily,
let alone exclusively, imply a change of a drug regimen, but
also comprises aspects such as dose increases of ongoing
therapy (where pertinent) or intra-articular glucocorticoid
injections, for example, in the presence of residual joint
swelling. The recommendation regarding the frequency of
treatment adjustments (the verbalisation ‘at least every
three months’ includes a higher frequency) is based on the
results of strategic clinical trials that showed that adapting
therapy every month leads to good outcomes compared
with conventional care.16 17 36 39 Recommending adjust-
ments in active disease ‘at least’ every three months, imply-
ing that this should not be later, is also based on evidence,
since the treatment response at 3 months allows to predict
if patients are highly likely or highly unlikely to achieve the
treatment target at subsequent points in time.38 87–89
Therefore, adjustments, potentially also a change of the
drug regimen, may have to be performed. Importantly, by
recommending to see these patients every three months,
this item indirectly will also serve the purpose of treatment
monitoring and prevention of overtreatment, yet another
important aspect in the context of treatment to target. The
term adjustment also comprises reduction or even with-
drawal of some therapies, when stability of the overall
response allows such decision to be made (see also item 9).
In any case, if medication is reduced or intervals prolonged,
the patients should be carefully watched by composite mea-
sures of disease activity to be sure that they do not experi-
ence a deterioration of their clinical status.
9. The desired treatment target should be maintained through-
out the remaining course of the disease. Unchanged
compared with 2010 (then no. 8), this item refers to obser-
vations that complete halt of joint damage and further
improvement of physical function depend on the mainten-
ance of the clinical remission state.11 58 90 Moreover, loss of
the targeted good outcome can reignite the process leading
to joint damage.91 92 Maintenance of the treatment target
does not in itself imply maintenance of treatment; indeed, a
number of studies on tapering of therapy, especially dose
reduction, interval increases and even withdrawal of biologi-
cals, have been performed since 2010.92–101 These studies
indicate that in established RA stopping biologicals leads to
very frequent loss of low-disease activity or remission, while
dose reduction or spacing of intervals of applications carries
less risk of return of active disease. In early disease, the
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question of successful withdrawal is not yet resolved.
Stopping conventional synthetic DMARDs102 is followed by
ﬂares more frequently compared with their continuation.103
In this context, the aspect of adherence to therapy has also
to be considered since non-adherent patients ﬂare up to four
times more frequently than adherent patients,104 pointing to
the signiﬁcant importance of information and shared
decision-making with the patients (items A and 10). Safety
aspects and drug costs may also have to be taken into consid-
eration in this respect.
10. The rheumatologist should involve the patient in setting the
treatment target and the strategy to reach this target. The
involvement of the patient in making decisions and the
type of information provided should be recorded, along
with the treatment target and the measures to be used
during follow-up. The agreed and documented target
should be visible in the patient records to every HCP
involved in the monitoring of the disease evolution of the
individual patient. Compared with previous no. 10, this
recommendation has not only been simpliﬁed, but a pro-
active role is now assigned to the rheumatologist (previ-
ously: ‘under the supervision of the rheumatologist’).
Rheumatologists, but also all other health professionals
caring for patients with RA, are reminded that the reasons
to propose a particular treatment target and the means to
achieve this ought to be not only properly communicated
to the patient, but also agreed upon with the patient, in
line with respective information on the disease and the ben-
eﬁts and risks of various therapies. Indeed, patients have a
wide range of beliefs related to DMARD therapy105 and
appropriate communication allows patients to make
informed decisions.106 Moreover, adherence to treatment
has been clearly shown to depend on the level of informa-
tion and on a good interaction with the rheumatologist.107
In this context, it also must be reiterated that patients with
RA require a multidisciplinary care and that in many coun-
tries nurse practitioners/specialists or other health profes-
sionals take a very important role in informing, following
and managing patients (see also overarching principle A).
Offering such care where available, or attempting to estab-
lish it, is also part of the overall role of the rheumatologist.
This item inherently comprises all aspects of the present
recommendations, such as the setting of the treatment
target, the means of disease evaluation, the chosen drug
and non-medical therapy including their risks, the focus on
comorbidities and other patient factors, the follow-up
process—all this has to be taken into consideration when
the rheumatologist ‘involves’ the patient. Indeed, it may be
challenging to explain to a patient whose disease activity
has signiﬁcantly improved that therapy should be intensi-
ﬁed—and these recommendations and especially their
patient version108 may be helpful to this end. Educational
programmes supporting this process need to be expanded.
DISCUSSION
Like the 2010 ‘treat-to-target’ recommendations, the updated
version is aimed at practising rheumatologists and other health
professionals caring for patients with RA; ofﬁcial bodies such as
governments or payers who may have an interest to assess clin-
ical practice in their environment; but also clinical trialists and
regulators, given that strategic trials have meanwhile become a
focus of industry-initiated studies after having had a sole investi-
gator initiated nature for long. Patients are another important
audience for whom a separate version is planned in line with
the 2010 recommendations.108
The procedures were initiated by a Steering Committee that
adhered to the EULAR operating procedures.109 The Steering
Committee solicited the SLRs.33 Based on this new evidence, a
large Task Force was convened comprising 43 individuals, of
whom 5 were patient representatives and 37 rheumatologists
from around the world. Contrasting the previous Task Force,
the current one also obtained input from a nurse specialist.
As before, the recommendations focused on a treatment
target that would allow for an optimal outcome of RA for the
individual patient. In contrast to guidance documents on the
management of RA with drugs,20 22 the present recommenda-
tions are of generic nature and do not address particular agents
or classes of drugs. The Task Force was aware that with different
accessibilities to certain medications overall outcomes may differ
between countries and regions,110 111 but a good outcome can
also be attained in a large proportion of patients with easily
accessible and affordable therapies, as long as a strategic treat-
ment approach is adhered to.16 112
The Task Force revisited the overarching principles and the
10 itemised recommendations and reiterated that a pivotal
aspect in the care of RA is the shared decision-making with the
patient. The whole set presented is framed by this aspect, with
overarching principle A introducing it and item 10 calling again
for the involvement of the patient in setting the goals and the
strategy. Overarching principle B has been amended to now
include work participation since this is not only an important
aspect related to overall quality of life,47 but an important
outcome that can be increasingly achieved with modern thera-
peutic strategies.
All Task Force members agreed unanimously that abrogation
of inﬂammation (overarching principle C) and thus reaching a
state of clinical remission (recommendation 1) is the most
important goal in the treatment of RA, at least in its early stages,
meaning ’the absence of signs and symptoms of signiﬁcant
inﬂammatory disease activity’ (recommendation 2). The new
ACR–EULAR remission deﬁnitions provide the assessment tools
that account for this principle. Less stringent criteria comprise
patients who have signiﬁcant residual inﬂammation, less func-
tional improvement and more damage progression, while poten-
tially more stringent targets, such as remission by sonography,
while having been discussed, have to await conclusive evidence
of better outcomes compared with the stringent ACR–EULAR
clinical criteria. Indeed, recommendations 1 and 2 remained
unchanged from the 2010 version, but are now supported by
more direct and indirect evidence.28 33 39 46 49 57 64 65
Also, recommendation 3, namely that low-disease activity con-
stitutes the alternative for remission, has not been changed and
was regarded equally important as item 1 by the Task Force. This
is particularly true for patients with long-standing disease who
will mostly not be able to achieve clinical remission. Indeed, low-
disease activity is the second best state, leading to much better
functional and structural as well as work-related outcomes than
moderate let alone high-disease activity.11 25 26 Indeed, most evi-
dence for the beneﬁt of targeting a good therapeutic outcome
compared with conventional care exists for the low-disease activ-
ity state target. Having deﬁned low-disease activity as the alterna-
tive target to remission implies that any higher disease activity
state would not be an acceptable outcome. However, this conclu-
sion is pertinent to the care of uncomplicated RA and may have
to be adjusted in line with recommendation 5, when comorbidity,
drug-related risks or other patient factors mandate to refrain
from intensifying therapy to reach the most desired target.
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Likewise, while usually composite measures of disease activity
that include joint counts, such as DAS, DAS28, CDAI or SDAI,
should be employed to assess disease activity during follow-up
(recommendation 4); other instruments may be a better choice to
evaluate disease activity if one or more components of the com-
posite measures are confounded by non-RA-related factors, espe-
cially comorbidities such as exaggerated pain sensitivity
(ﬁbromyalgia); this aspect is encompassed in item 5. On the
other hand, in the course of caring for our patients we need to
bear in mind that drugs are not the only therapeutic approach,
and sometimes interventions, such as physiotherapy, surgical pro-
cedures to prevent tendon rupture or a particular focus on foot-
care,113 may be helpful and important.
Recommendation 6 addresses the need for regular assessment
of disease activity and its documentation. The major change here
is the deletion of a 3-month assessment if the treatment target is
maintained; the Task Force felt that once the desired state is
achieved for prolonged periods of time, less frequent assess-
ments, such as every six -months (or less), is sufﬁcient. The term
‘sustained’ is important in this respect since if the targeted status
is achieved for the ﬁrst time additional control examinations to
ensure maintenance of the therapeutic success are usually
needed. Recommendation 7 now refers to comorbidity in add-
ition to structural damage progression and functional impair-
ment. Usually, joint damage will not progress in sustained clinical
remission but may increase slightly in low-disease activity. Thus,
addressing destruction may be particularly pertinent to a state of
low-disease activity that, should damage be rapidly progressing
or functional impairment increase, may require intensiﬁcation of
therapy. However, comorbidity may also require adaptation of
treatment, such as withdrawal or dose reduction of certain
agents. On the other hand, it should be borne in mind that some
comorbidities may be a consequence of inﬂammation and their
prevention may require more intensive therapy.
As recommended in item 8, the adjustment of therapy in
accordance with disease activity under the provisos discussed
above is a pivotal item in the treatment strategy. It was shifted
from position 4 to 8 for two reasons: ﬁrst, it is only logical that
before making treatment decisions disease activity has to be
assessed and all factors pertaining to the treatment decision,
starting with the target and ending with thoughtfulness regard-
ing disease activity assessment, that is, recommendations 1–7,
have to be accounted for; second, the need to control disease by
therapeutic adaptations is implicitly included in several of the
prior recommendations, namely items 4–6 (disease activity
assessment), but also in items 1–3 (treatment target): how else
than by treatment adaptation would one usually reach the treat-
ment target? All the evidence currently available relates to such
therapeutic adjustments at 1-to-3-month intervals—this is the
foundation of treatment success, based on regular disease activ-
ity assessment and deﬁnition of a treatment target.33 The subse-
quent recommendation relates to the maintenance of the
treatment target and implicitly includes the possibility to taper
therapy by reducing dose or expanding intervals between appli-
cations, whether csDMARDs or bDMARDs.
During the 5 years since the ﬁrst formulation of the recom-
mendations, we have witnessed an increasing proportion of
patients in low-disease activity or remission, both in clinical trials
and observational studies, especially when the treat-to-target
strategy is employed.92 99 100 114–117 The amended set of recom-
mendations may allow for even further improvement as we have
addressed aspects of work productivity and comorbidities more
clearly and have strengthened the advice to not only evaluate
disease activity but also record it in conjunction with recording
the treatment target and strategy as well as the information given
to the patient. This documentation is of particular importance in
settings where patients are seen by different rheumatologists in
the course of their disease, but are also a good prompt in all
situations of interactions between patients with RA and health
professionals.
The updated recommendations constitute a major advance-
ment when compared with the 2010 version because several of
the items are now based on much better evidence. In particular,
the SLR has now revealed evidence for the validity and effect-
iveness of the T2T approach also in patients with established RA
(before evidence existed only for early RA); for remission as a
Figure 1 Algorithm of treating rheumatoid arthritis (RA) to target based on the updated recommendations provided in the table 1 and discussed
in detail in the ’Results’ section. Indicated as separate threads are the main target (remission and sustained remission) and the alternative target
(low-disease activity in patients with long-term disease and sustained low-disease activity), but the approaches to attain the targets and sustain
them are essentially identical. Adaptation of therapy should be usually done by performing control examinations with appropriate frequency and
using composite disease activity measures that comprise joint counts, but should take comorbidities and other patient factors into account. Setting
the target as well start and adaptation of therapy should be done as a shared decision with the patient.
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treatment target (rather than only low-disease activity as
before); and for the effect of a T2T approach on working
ability. In addition, several items were strengthened by the new
evidence. Overall, this also led to a dramatic change in the level
of evidence: while originally only two recommendations had an
evidence level of 1 or 2, now 7 of them are based on such high
levels. Moreover, four recommendations in 2010 had levels of
agreement of <9.0, while now all recommendations achieved
agreement levels of ≥9.0, indicating that the members of the
Task Force felt much more conﬁdent with the 2014 recommen-
dations than was the case a few years ago. Moreover, the
updated recommendations focus more strongly than the original
version on the individual patient level since they more clearly
address aspects of daily life that patients are rooted in, such as
return to work, as well as comorbidity. They continue to empha-
sise the importance of shared decision-making with the patient.
All this is also reﬂected in the algorithm depicting the recom-
mendations in a graphic way (ﬁgure 1).
The research agenda for a potential next revision of these
recommendations is inherent in the open question discussed
before. To name a few: (i) Is attaining imaging remission super-
ior to stringent clinical remission (ACR–EULAR) regarding
structural and functional outcomes? (ii) If imaging remission
provides statistically superior radiographic and functional out-
comes compared with stringent clinical remission, is it of clin-
ical signiﬁcance that makes it worth the effort and risk of
controlling patients regularly by sonography and intensifying
therapy? (iii) Which measures of disease activity could be reli-
ably used to evaluate patients with RA with particular pain sen-
sitivity? (iv) Is monthly adaptation of therapy16 superior to
adaptations done every three months?118 (v) How much
improvement in outcomes do well informed patients experi-
ence compared with less informed patients? Finally, another
important research item relates to (vi) adherence of T2T strat-
egies in clinical practice.
While recommendations like the ones presented here may be
able to summarise the current state of evidence and provide the
respective target audience with some guidance, their implemen-
tation is difﬁcult to follow. Evaluating the implementation of
the T2T strategy is clearly an additional important research
aspect of the future. To this end, it must be borne in mind that
the success of T2T implementation, even if it constitutes a
generic concept, may be different in different areas of the
world. However, despite such differences the T2T concept is
helpful for all societies, as so nicely summarised in a recent
reﬂection on the situation in Russia.119
In summary, the updated version of the treat-to-target recom-
mendations have brought this guidance document to a new level
regarding evidence and agreement and will hopefully be
adopted by the community of rheumatologists, patients and the
other stakeholders.
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